These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 35779655)

  • 1. Cyclodextrin-mediated conjugation of macrophage and liposomes for treatment of atherosclerosis.
    Gao C; Liu C; Chen Q; Wang Y; Kwong CHT; Wang Q; Xie B; Lee SMY; Wang R
    J Control Release; 2022 Sep; 349():2-15. PubMed ID: 35779655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming.
    Zimmer S; Grebe A; Bakke SS; Bode N; Halvorsen B; Ulas T; Skjelland M; De Nardo D; Labzin LI; Kerksiek A; Hempel C; Heneka MT; Hawxhurst V; Fitzgerald ML; Trebicka J; Björkhem I; Gustafsson JÅ; Westerterp M; Tall AR; Wright SD; Espevik T; Schultze JL; Nickenig G; Lütjohann D; Latz E
    Sci Transl Med; 2016 Apr; 8(333):333ra50. PubMed ID: 27053774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anchoring β-CD on simvastatin-loaded rHDL for selective cholesterol crystals dissolution and enhanced anti-inflammatory effects in macrophage/foam cells.
    He J; Zhou X; Xu F; He H; Ma S; Liu X; Zhang M; Zhang W; Liu J
    Eur J Pharm Biopharm; 2022 May; 174():144-154. PubMed ID: 35447349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macrophage Membrane-Encapsulated Dopamine-Modified Poly Cyclodextrin Multifunctional Biomimetic Nanoparticles for Atherosclerosis Therapy.
    Zhu L; Zhong Y; Yan M; Ni S; Zhao X; Wu S; Wang G; Zhang K; Chi Q; Qin X; Li C; Huang X; Wu W
    ACS Appl Mater Interfaces; 2024 Jun; 16(25):32027-32044. PubMed ID: 38867426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shuttle/sink model composed of β-cyclodextrin and simvastatin-loaded discoidal reconstituted high-density lipoprotein for enhanced cholesterol efflux and drug uptake in macrophage/foam cells.
    He J; Yang Y; Zhou X; Zhang W; Liu J
    J Mater Chem B; 2020 Feb; 8(7):1496-1506. PubMed ID: 31999290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-proinflammatory and responsive nanoplatforms for targeted treatment of atherosclerosis.
    Dou Y; Chen Y; Zhang X; Xu X; Chen Y; Guo J; Zhang D; Wang R; Li X; Zhang J
    Biomaterials; 2017 Oct; 143():93-108. PubMed ID: 28778000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-19 Halts Progression of Atherosclerotic Plaque, Polarizes, and Increases Cholesterol Uptake and Efflux in Macrophages.
    Gabunia K; Ellison S; Kelemen S; Kako F; Cornwell WD; Rogers TJ; Datta PK; Ouimet M; Moore KJ; Autieri MV
    Am J Pathol; 2016 May; 186(5):1361-74. PubMed ID: 26952642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conjugation of Macrophage-Mimetic Microalgae and Liposome for Antitumor Sonodynamic Immunotherapy via Hypoxia Alleviation and Autophagy Inhibition.
    Gao C; Kwong CHT; Wang Q; Kam H; Xie B; Lee SM; Chen G; Wang R
    ACS Nano; 2023 Feb; 17(4):4034-4049. PubMed ID: 36739531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclodextrin boostered-high density lipoprotein for antiatherosclerosis by regulating cholesterol efflux and efferocytosis.
    Wang Y; Gao H; Huang X; Chen Z; Kang P; Zhou Y; Qin D; Zhang W; Liu J
    Carbohydr Polym; 2022 Sep; 292():119632. PubMed ID: 35725197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Desmosterol suppresses macrophage inflammasome activation and protects against vascular inflammation and atherosclerosis.
    Zhang X; McDonald JG; Aryal B; Canfrán-Duque A; Goldberg EL; Araldi E; Ding W; Fan Y; Thompson BM; Singh AK; Li Q; Tellides G; Ordovás-Montanes J; García Milian R; Dixit VD; Ikonen E; Suárez Y; Fernández-Hernando C
    Proc Natl Acad Sci U S A; 2021 Nov; 118(47):. PubMed ID: 34782454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioinspired PROTAC-induced macrophage fate determination alleviates atherosclerosis.
    Huang JH; Huang CJ; Yu LN; Guan XL; Liang SW; Li JH; Liang L; Wei MY; Zhang LM
    Acta Pharmacol Sin; 2023 Oct; 44(10):1962-1976. PubMed ID: 37169852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with KLEPTOSE® CRYSMEB reduces mouse atherogenesis by impacting on lipid profile and Th1 lymphocyte response.
    Montecucco F; Lenglet S; Carbone F; Boero S; Pelli G; Burger F; Roth A; Bertolotto M; Nencioni A; Cea M; Dallegri F; Fraga-Silva RA; Fougère L; Elfakir C; Gassner AL; Rudaz S; Parissaux X; Wils D; Salomé M; Vuilleumier N; Poggi A; Mach F
    Vascul Pharmacol; 2015 Sep; 72():197-208. PubMed ID: 25921922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Folate-Modified Liposomes Loaded with Telmisartan Enhance Anti-Atherosclerotic Potency for Advanced Atherosclerosis in ApoE
    Fang D; Jin Q; Jin Z; Wang F; Huang L; Yang Y; He Z; Liu Y; Jiang C; Wu J; Song X
    J Biomed Nanotechnol; 2019 Jan; 15(1):42-61. PubMed ID: 30480514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Ultrasound-Responsive Theranostic Cyclodextrin-Loaded Nanoparticle for Multimodal Imaging and Therapy for Atherosclerosis.
    Mehta S; Bongcaron V; Nguyen TK; Jirwanka Y; Maluenda A; Walsh APG; Palasubramaniam J; Hulett MD; Srivastava R; Bobik A; Wang X; Peter K
    Small; 2022 Aug; 18(31):e2200967. PubMed ID: 35710979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reactive oxygen species (ROS)-responsive size-reducible nanoassemblies for deeper atherosclerotic plaque penetration and enhanced macrophage-targeted drug delivery.
    He J; Zhang W; Zhou X; Xu F; Zou J; Zhang Q; Zhao Y; He H; Yang H; Liu J
    Bioact Mater; 2023 Jan; 19():115-126. PubMed ID: 35475030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bifunctional supramolecular nanofiber inhibits atherosclerosis by enhancing plaque stability and anti-inflammation in apoE
    Shang Y; Ma C; Zhang J; Wang Z; Ren C; Luo X; Peng R; Liu J; Mao J; Shi Y; Fan G
    Theranostics; 2020; 10(22):10231-10244. PubMed ID: 32929345
    [No Abstract]   [Full Text] [Related]  

  • 17. β-Cyclodextrin and Hyaluronic Acid-Modified Targeted Nanodelivery System for Atherosclerosis Prevention.
    Yu J; Ma Y; Zhang X; Wang S; Zhou L; Liu X; Li L; Liu L; Song H; Luo Y; Wen S; Li W; Niu X
    ACS Appl Mater Interfaces; 2024 Jul; 16(27):35421-35437. PubMed ID: 38940349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homocysteine accelerates atherosclerosis via inhibiting LXRα-mediated ABCA1/ABCG1-dependent cholesterol efflux from macrophages.
    Jin P; Bian Y; Wang K; Cong G; Yan R; Sha Y; Ma X; Zhou J; Yuan Z; Jia S
    Life Sci; 2018 Dec; 214():41-50. PubMed ID: 30393020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macrophage Lxrα reduces atherosclerosis in Ldlr
    Yin Y; Zeng S; Li Y; Wu Z; Huang D; Gao P
    Biochem Biophys Res Commun; 2020 Aug; 529(3):540-547. PubMed ID: 32736671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical Reversal of Atherosclerosis by FDA-Approved Compound that Transforms Cholesterol into an Anti-Inflammatory "Prodrug".
    Mendelsohn AR; Larrick JW
    Rejuvenation Res; 2016 Jun; 19(3):252-5. PubMed ID: 27241174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.